Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients

NCT02659397 is registered in ClinicalTrials.gov with Esperion Therapeutics, Inc. as lead sponsor.

NCT NCT02659397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients
Lead sponsor
Esperion Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2015
Completion date
July 31, 2016
Enrollment
68 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia